{"id":165576,"name":"PURDUE PHARMA LLP","slug":"purdue-pharma-llp","state":"DC","country":"United States of America","description":"","totalSpending":1700000,"filings":34,"yearlySpending":[{"year":2018,"income":200000},{"year":2019,"income":200000},{"year":2020,"income":200000},{"year":2021,"income":200000},{"year":2022,"income":250000},{"year":2023,"income":200000},{"year":2024,"income":200000},{"year":2025,"income":250000}],"issues":["HCR","PHA","MMM","BUD","BNK"],"firms":["CAPITOL HILL CONSULTING GROUP"],"lobbyists":["BRIAN SUTTER","DAVID EDWARDS","DAVID JORY","THOMAS WHARTON","EMILY WILKINSON-HOLLAND","CHRISTOPHER DAVIS"],"govEntities":["Health & Human Services, Dept of (HHS)","HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["Issues related to prescription drug abuse; issues related to abuse deterrent formulations; issues related to Medicaid rebates; issues related to implementation of the Affordable Care Act;","Controlled Drug Substances Act (21 USC 13)","General Medicare and Medicaid issues including, but not limited to, coverage reimbursement, payments and rebates","Issues related to Labor-HHS funding. Issues related to funding of the 21st Century Cures Act.","General Medicare and Medicaid issues including, but not limited to, coverage reimbursement, payments and rebates"],"years":[2018,2019,2020,2021,2022,2023,2024,2025]}